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Irritable bowel syndrome (IBS) is the most common of the functional gastrointestinal
disorders (FGIDs). Despite its prevalence and health-care costs, there are few effective
therapies for patients with severe symptoms. Our objective was to determine whether
surgical management would improve health-related quality of life (HRQOL) in severe
refractory constipation-dominant FGIDs. From 2003 to 2005, 6 patients underwent total
colectomy with end ileostomy or primary anastomosis. They completed Short Form 36
(SF-36) and IBS-36 questionnaires preoperatively and postoperatively. HRQOL was
compared with age- and sex-matched Canadian norms using Welch’s unpaired t test.
Preoperative SF-36 physical and mental health summary scores were significantly lower
than Canadian norms (P , 0.0001), while postoperative scores were not significantly
different than Canadian norms (P ¼ 0.50 and P ¼ 0.57, respectively). After surgical
management, HRQOL in patients with severe constipation-dominant IBS improved from
drastically below that of Canadian norms to a comparable level. This finding questions
the convention of avoiding operations in IBS patients and demonstrates that surgical
management may be suitable for the appropriately screened patient.
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general convention to avoid operating on patients
with IBS and other FGIDs for the purpose of
symptom control.14–17 Nevertheless, there are some
motility-disordered patients who have such intractable symptoms as to severely diminish their quality
of life. These patients have received operative
management aimed at ameliorating their symptoms
and thus improving their lives. At our tertiary care
center, we have identified a group of such motilitydisordered patients. Patient accounts of their disease
experience relate severe pain and constipation
leading to debilitating loss of daily functioning,
emotional distress, disability, and impaired quality
of life. The objective of this study was to determine
whether surgical management of severe refractory
constipation-dominant motility disorders in adult
patients would result in improved HRQOL.

Materials and Methods
This study was approved by the institutional
research ethics board. The study population was
drawn from patients referred to a colorectal motility
clinic at a Canadian tertiary care center from 1996 to
2003. These patients were referred for consideration
of surgical management for their motility disorder.
Between 2003 and 2005, all such patients who
underwent surgical management, including bowel
resection, were approached to be involved in this
study. All patients who met inclusion criteria and
gave informed consent were consecutively sampled.
Inclusion criteria were the following: adult (age 18
years), diagnosis of GI motility disorder, and
upcoming bowel resection for management of
motility disorder. In order to exclude nonmotility
disorders or mechanical causes of obstruction, all of
these patients were evaluated thoroughly. Work-up
included, but was not limited to, upper and lower
GI endoscopy, barium swallow, colonic transit
studies, and esophageal and anal manometry.
Within 1 month before their surgery, all eligible
patients completed preoperative Short Form 36 (SF36) and Irritable Bowel Syndrome 36 (IBS-36)
quality-of-life questionnaires. The SF-36 is a generic
HRQOL scale that has been well validated in
various clinical settings as well as at the population
level.18,19 It has 8 domains, each scored from 0 to
100. The domains are as follows: physical function,
role physical, pain, role emotional, energy/fatigue,
emotional well-being, social function, and general
health. These domains can be summarized by a
Physical Health Summary score and a Mental
Health Summary score. The IBS-36 is a wellInt Surg 2015;100
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rritable bowel syndrome (IBS) is one of 20
functional gastrointestinal disorders (FGIDs).
These are a heterogeneous group of chronic disorders in which the presenting gastrointestinal (GI)
symptoms cannot be explained by structural or
biochemical abnormalities.1,2 IBS is characterized by
abdominal pain associated with defecation, change
in bowel habit, bloating, and distension.3,4 The
ROME III committee developed a set of diagnostic
criteria for each FGID separately.3,4 However, it has
become increasingly accepted that the FGIDs overlap considerably and therefore, IBS should not be
considered as a single entity but rather on a
spectrum of related disorders.1,5
IBS is the most common of the FGIDs with a
prevalence rate in the United States anywhere from
3% to 20%, with most studies quoting around
10%.1,2 Although up to 70% of IBS sufferers in the
United States do not seek medical attention, the total
health-care costs and burden to the health-care
system is substantial.5,6 In fact, in the United States,
among GI illnesses, IBS was second only to
gastroesophageal reflux disease in prevalence in a
comprehensive assessment of burden of illness.5 In
addition, the estimated direct and indirect annual
health-care costs of IBS in the United States are $1.6
billion and $19.2 billion, respectively.1,5 Despite the
high expenditure for this illness, there are very
limited effective treatment options, and patients
continue to demonstrate poor health-related quality
of life (HRQOL), which is comparable to that seen in
patients with organic disease.1,7–12
Treatment options have largely been directed at
symptom relief and vary depending on symptom
severity. They include any and all of the following:
education and reassurance, diet and lifestyle modification, pharmacotherapy directed at relief of
bowel-specific symptoms with medications (such
as anticholinergics, antispasmodics, antidiarrheals,
and laxatives), as well as antidepressants and
narcotics, along with referrals to mental health and
pain services.2,5,13 A combination of the above
therapies has been somewhat effective in patients
with mild to moderate symptoms; however, in
moderate to severe cases, patients often have
symptoms that are refractory and persistent despite
exhaustive use of the above modalities.
Patients who suffer from severe symptoms of IBS
commonly present with a picture of acute severe
abdominal and/or pelvic pain and frequently
undergo unnecessary emergent abdominopelvic
surgeries.14–17 As the literature would suggest, these
surgeries are often nontherapeutic, and thus it is a
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Table 1 Patient demographic and clinical characteristics, including CCI

Patient
1
2
3
4
5
6

Age at
onset

Sex

40s
Unknown
Teens
40s
Childhood
Unknown

Female
Female
Female
Female
Female
Female

Diagnosis
Motility
Motility
Motility
Motility
Motility
Motility

disorder
disorder
disorder
disorder
disorder
disorder

Type (constipation/
diarrhea)

Stool frequencya

CCI

CCI
(age-adjusted)

Constipation
Constipation
Constipation
Constipation
Constipation
Constipation

Every 2 weeks
Every 3 to 4 days
Every 3 to 4 days
Requires daily enemas
Once a week
Every 3 days

1
0
1
0
1
1

2
3
1
0
2
2

All stool frequencies were reported as occurring with the patients’ use of laxatives..

validated condition-specific HRQOL scale that was
developed and validated using Canadian IBS
patients.20 Postoperatively, these patients again
completed the SF-36 and IBS-36 questionnaires
between 6 and 9 months after their surgery.
Demographic and symptom-related (e.g., frequency of bowel movements) data were collected
prospectively. A Charlson Comorbidity Index (CCI)
was calculated for each person using these data. The
CCI is a well-validated and widely used prognostic
measure; in our study, it was employed to adjust for
the burden of preexisting comorbidities and the
potential effect it may have played on both
preoperative and postoperative HRQOL.21–28 The
preoperative and postoperative SF-36 Physical
Health and Mental Health Summary scores were
compared with age- and sex-matched mean scores
for Canadians. The Canadian normative SF-36 data
were based on a large multi-centered communitybased study conducted in 1996–1997 and sampling
within a 50-km radius of 9 Canadian cities stretching
from Vancouver to St. John’s.29 Welch’s unpaired t
test was used to assess for significant differences
between Canadian mean Summary Health scores
and the mean Summary Health scores of the study
population. Although a nonparametric test such as a
Mann-Whitney U test would have been more
appropriate, given the small sample size, the
Canadian normative population data were only
available in mean 6 SD format and precluded the
use of nonparametric tests. Thus, Welch’s unpaired t
test was used; this test does not assume equal
variances between samples and is thus more
conservative than the Student t test. An a of 0.05
was set as the threshold for rejecting the null
hypothesis of no significant difference.
Change scores (postoperative minus preoperative) were calculated for IBS-36 and SF-36 Physical
Health and Mental Health Summary scores. In order
to standardize the change scores against the
Canadian normative data, standardized z scores
Int Surg 2015;100

were calculated for each SF-36 Physical Health and
Mental Health Summary score in this study population. For example, this was done as follows for the
Physical Health Summary score: patient Physical
Health Summary score minus age- and sex-matched
mean Canadian Physical Health Summary score, all
divided by the SD for that age- and sex-matched
mean Canadian Physical Health Summary score.
Generalized linear models using type-III analysis of
model effects were performed with change scores as
the scale response (i.e., dependent) variable and the
following predictor variables: surgery type and
presence of histopathologic abnormalities in resected bowel specimen. Three separate models were
performed for the change scores in IBS-36 and SF-36
Physical Health and Mental Health Summary
scores. Sensitivity analyses for the SF-36 change
scores were conducted by performing generalized
linear models with change in standardized z score as
the dependent variable. All analyses were performed using the SPSS/PASW (SPSS Version 21.0.,
IBM Corp., Armonk, NY) statistical package.

Results
From 1996 to 2003, 98 patients were referred to the
motility clinic for consideration of surgical management. Between 2003 and 2005, 7 patients met
inclusion criteria. Of these, 6 patients completed
both preoperative and postoperative HRQOL questionnaires.
The patients were all female. Most had disease
onset ranging from childhood to their 40s (Table 1).
They presented with constipation-dominant symptoms, with frequency of bowel movements ranging
from once every 3 to 4 days to once every 2 weeks
despite use of laxatives (Table 1). Charlson Comorbidity Indices (CCI) were either 0 or 1; age-adjusted
CCIs ranged from 0 to 3 (Table 1). These patients
presented with disordered motility in more than one
part of their GI tract. Table 2 depicts the results of
65
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Table 2 Patient dysmotility profile following preoperative work-up

Patient
1
2
3
4
5
6

GU
dysmotility

Esophageal
dysmotility

Gastric
dysmotility

Colonic
dysmotility

Anal outlet
obstruction

Intussusception

Rectocele

Yes
Yes
Yes
Yes
No
Yes

Yes
No
No
No
No
No

Yes
No
Yes
No
Yes
Yes

Yes
Yes
Yes
Yes
Yes
Yes

Yes
No
Yes
No
Yes
No

No
No
Yes
No
No
No

No
No
No
No
No
No

preoperative work-up. Most patients underwent
total colectomy and ileostomy, while 2 patients
underwent colectomy and ileorectal anastomosis;
one of the patients with ileorectal anastomosis also
had a diverting loop ileostomy (Table 3). Histopathologic abnormalities were noted in 2 patients; these
were myenteric plexus hypertrophy and melanosis
coli (Table 3).
The mean (6SD) preoperative SF-36 Physical
Health and Mental Health Summary scores were
13.28 (5.93) and 19.74 (10.16), respectively. The mean
(6SD) postoperative SF-36 Physical Health and
Mental Health Summary scores were 50.42 (23.54)
and 51.68 (20.95), respectively. The preoperative SF36 Physical Health and Mental Health Summary
scores were significantly lower than the age- and
sex-matched mean scores for Canadians (Welch’s t
test P , 0.0001 for both). The postoperative SF-36
Physical Health and Mental Health Summary scores
were not significantly different from the age- and
sex-matched mean scores for Canadians (Welch’s t
test P ¼ 0.50 and P ¼ 0.57, respectively) (Fig. 1). All
but 1 patient had improved postoperative IBS-36
scores (Fig. 2).
The generalized linear model analysis showed
that having a colectomy and ileostomy rather than
doing an ileorectal anastomosis was also significantly associated with improved postoperative Physical
and Mental Health summary scores (P ¼ 0.02 and P
¼ 0.01, respectively); sensitivity analysis using
change in standardized z score also showed a
significant association (P ¼ 0.008 and P ¼ 0.006,

respectively). Having a colectomy and ileostomy
rather than doing an ileorectal anastomosis was also
significantly associated with improved postoperative IBS-36 scores (P , 0.0001). Presence of
histopathologic findings (e.g., prominent myenteric
plexus, melanosis coli) in the resected bowel
specimens was also significantly associated with
improved postoperative IBS-36 scores (P ¼ 0.02).

Discussion
The preoperative SF-36 Physical and Mental Health
Summary scores were found to be significantly
below that of Canadian norms (P , 0.001 for both).
The change between preoperative and postoperative
scores was quite large in most patients. More
important, the postoperative SF-36 Physical and
Mental Health Summary scores were not significantly different than Canadian norms (P ¼ 0.50, and
P ¼ 0.57, respectively). Similarly, most patients
showed an improvement in their IBS-36 score after
surgery. Although the minimally important difference (MID) in SF-36 score has not been validated in
this population, a change of 3 to 5 points on the
summary score is considered a robust MID for the
SF-36 across many different conditions.30,31 With the
exception of the Mental Health Summary score for 1
patient, all change scores exceeded the MID of 3 to 5
points. There are no data on the MID for the IBS-36
scale. Our finding that the HRQOL of patients with

Table 3 Type of surgery and histopathology of surgical specimen
Patient
1
2
3
4
5
6

66

Surgery

Bowel histopathology

Colectomy and ileostomy
Colectomy and ileorectal anastomosis
Colectomy, ileorectal anastomosis, diverting ileostomy
Colectomy and ileostomy
Colectomy and ileostomy
Colectomy and ileostomy

No reported abnormalities
Melanosis coli
No reported abnormalities
No reported abnormalities
Normal
Prominent myenteric plexus

Int Surg 2015;100
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lower score indicates a better HRQOL.

Fig. 1 Preoperative and postoperative SF-36 scores depicted
with age- and sex-matched Canadian norms 6 SD. (A) Physical
Health Summary scores (P , 0.0001 and P ¼ 0.50, respectively).
(B) Mental Health Summary scores (P , 0.0001 and P ¼ 0.57,
respectively). PH, physical health; MH, mental health.

FGIDs is markedly lower than national norms is
consistent with the literature.1,7–12
Our findings also suggest that surgical management aimed at ameliorating symptoms of severe
refractory motility disorders may result in significantly increased HRQOL. Furthermore, not only
does this increased HRQOL appear to be clinically
significant but it also appears to be elevated to a
level that is comparable to age- and sex-adjusted
Canadian norms.
In the generalized linear model analysis, we
found a number of predictors of improved postoperative HRQOL. It has been conventional thought
that motility disorders are functional in nature and
do not have an organic pathophysiology behind
their presence. However, we found that a predictor
of improved HRQOL postoperatively was the
presence of some form of histopathologic abnormality within the resected specimen. Thus, our findings
suggest that an identifiable histopathologic abnormality is associated with improvement of HRQOL
after surgery for management of severe motility
disorders. Of interest, there has been recent work
looking into the possibility of abnormalities within
the enteric neurohormonal system that could be
associated with the disorder, specifically changes in
the myenteric plexus, number of glial cells, and
Int Surg 2015;100

interstitial cells of Cajal.32–34 Although currently
there have been no conclusive data showing an
association, there is ongoing research. Identification
of histopathologic abnormalities that are associated
with motility disorders and improved postoperative
HRQOL could potentially allow for screening of this
challenging patient population and allow for targeted surgical management in those most likely to
benefit.
Our findings also suggest that colectomy and
ileostomy result in better postoperative HRQOL
than a colectomy and ileorectal anastomosis. This
suggests that, contrary to patients’ usual preoperative desires, patients with an ileostomy tend to have
better HRQOL than those who have intact intestinal
continuity. Anecdotally, this finding is generally
reflected in patients managed in our clinic prior to
and following this study period. In general, patients
tend to abhor the idea of an ostomy when it is first
presented to them and, in some cases, refuse to
consider the functional benefits of an ileostomy over
an ileorectal anastomosis. In some patients, the
functional consequences (e.g., constant washroom
trips, fecal/flatal incontinence, persistent nausea
and vomiting) of an ileorectal anastomosis eventually lead to conversion to an ostomy. In these
patients, their quality of life tends to improve,
although these are anecdotal observations and have
not been subjected to standardized pre- or postassessment. Of interest, our finding of better
HRQOL with an ileostomy rather than an ileorectal
anastomosis is apparent and detectable even at this
early point (i.e., within the first post-op year). Based
on our anecdotal experience, we would expect a
more pronounced difference in quality of life 2 or 3
years after surgery. Often, we have observed that
patients with ostomies are still trying to come to
terms with having an ostomy in the year or 2
following surgery and thus may appear to have a
67
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justify a controlled trial with the use of sham
surgery. Nevertheless, the risk of bias introduced
by a potential placebo effect is an important
consideration that should be addressed in future
studies.
In conclusion, HRQOL of patients with severe
constipation-dominant motility disorders refractory
to medical management is drastically below that of
age- and sex-matched Canadian norms. Our findings suggest that surgical management, specifically
total colectomy and ileostomy, aimed at controlling
refractory symptoms was successful in improving
HRQOL to a level comparable to age- and sexmatched Canadian norms. Our findings suggest that
an identifiable histopathologic bowel abnormality is
associated with improvement of HRQOL after
surgery for management of severe motility disorders. Although it has been common practice in the
past to avoid operations in patients with FGIDs, the
results of this study suggest that specific surgical
management may in fact be a suitable treatment
option in the appropriately screened patient. However, as this study is small, our findings, although
statistically and clinically significant, are not sufficient to drive changes in clinical practice. Larger
studies are needed. More important, we need to
challenge the assumption that all patients with
FGIDs are devoid of organic disease and thus
should never be offered surgical management. A
significant barrier to accruing larger sample sizes for
this study was the resistance of surgeons to offer this
modality of treatment because of the belief that
patients will universally have bad outcomes. The
findings of this small study may call that assumption into question enough that surgeons may be
more willing to selectively offer this management
modality in the context of a study.

References
1. Talley NJ. Functional gastrointestinal disorders as a public
health problem. Neurogastroenterol Motil 2008;20(1):121–129
2. Ringel Y, Sperber AD, Drossman DA. Irritable bowel
syndrome. Annu Rev Med 2001;52:319–338
3. Drossman DA. The functional gastrointestinal disorders and
the Rome III process. Gastroenterol 2006;130(5):1377–1390
4. Longstreth GF, Thompson WG, Chey WD, Houghton LA,
Mearin F, Spiller RC. Functional bowel disorders. Gastroenterol
2006;131(2):1480–1491
5. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA
technical review on irritable bowel syndrome. Gastroenterol
2002;123(6):2108–2131
Int Surg 2015;100

Downloaded from http://meridian.allenpress.com/international-surgery/article-pdf/100/1/63/2215111/intsurg-d-13-00212_1.pdf by guest on 28 June 2022

diminished HRQOL as compared with those without ostomies. Conversely, patients without ostomies
are so glad to have avoided an ostomy that they
initially ignore or minimize the undesirable functional consequences of their ileorectal anastomosis.
The major weakness of this study is the small
sample size. However, considering the large effect
seen in this study, it would be prudent to follow this
study with a larger one. One of the barriers to larger
sample sizes is the low incidence of patients that
would receive these surgeries for the management
of severe motility disorders. Thus, a multi-centered
approach would be required. Another barrier is the
resistance of surgeons to offer this modality of
treatment because of the belief that patients will
universally have bad outcomes. The results presented here may provide enough doubt to that assumption that surgeons may be willing to participate in a
study examining the efficacy of this treatment
strategy.
Another weakness of this study was the use of
Welch’s unpaired t test. Although a nonparametric
test such as a Mann-Whitney U test would have
been more appropriate, given the small sample size,
the Canadian normative population data were only
available in mean 6 SD format and precluded the
use of nonparametric tests. Thus, Welch’s unpaired t
test was used; this is a parametric test, like the
Student t test, except that it does not assume equal
variances between samples and is thus more
conservative. Although the use of a parametric test
in this instance was suboptimal, the mitigating
factor is that the P values were starkly on either
side of significance (i.e., the significant P values were
both ,0.0001, and the nonsignificant ones were
.0.5). Thus, there were no P values at or around P ¼
0.05, where we would worry that having done
another test may have tipped it over the threshold in
either direction.
Finally, this patient population represents a group
of individuals who have endured debilitating
symptoms with no benefit from medical therapy.
On presentation for surgical assessment, they are
aware that surgical therapy is the last option
available and are desperate for symptom alleviation.
Given this scenario, it may be possible that the
benefits seen after operative management represent
a placebo effect. To elucidate whether the improved
HRQOL seen with surgical management is related
to the surgery itself versus a placebo effect, a study
would have to incorporate a control group of
patients who receive sham surgery. However, at
present, there is insufficient evidence to ethically

HRQOL AFTER SURGERY FOR CONSTIPATION-DOMINANT IBS

HRQOL AFTER SURGERY FOR CONSTIPATION-DOMINANT IBS

6. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery:

LAM

22. Singh B, Bhaya M, Stern J, Roland JT, Zimbler M, Rosenfeld

a multivariable analysis. Gastroenterol 2004;126(7):1665–1673

RM et al. Validation of the Charlson comorbidity index in

7. Spiegel BMR. The burden of IBS: looking at metrics. Curr

patients with head and neck cancer: a multi-institutional

Gastroenterol Rep 2009;11(4):265–269
8. Lea R, Whorwell PJ. Quality of life in irritable bowel
syndrome. Pharmacoeconomics 2001;19(6):643–653
9. Longstreth GF, Bolus R, Naliboff B, Chang L, Kulich KR,

study. Laryngoscope 1997;107(11):1469–1475
23. Fowler JE, Terrell FL, Refroe LC. Co-morbidities and survival
of men with localized prostate cancer treated with surgery or
radiation therapy. J Urol 1996;156(5):1714–1718
24. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing

patients’ lives: development and psychometric documentation

risk analysis of men aged 55 to 74 years at diagnosis managed

of a disease-specific measure for use in clinical trials. Eur J

conservatively for clinically localized prostate cancer. JAMA

Gastroenterol and Hepatol 2005;17(4):411–420

1998;280(11):975–980

10. El-Serag HB, Olden K, Bjorkman D. Health-related quality of

25. Hall W, Ashesh JB, Ryu JK, Narayan S, Vijayakumar S. The

life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002;16(6):1171–1185

impact of age and comorbidity on survival and treatment
patterns in prostate cancer: using the Charlson Comorbidity

11. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The

Index to improve outcomes. Prostate Cancer Prostatic Dis 2005;

impact of irritable bowel syndrome on health-related quality
of life. Gastroenterol 2000;119(3):654–660
12. Luscombe FA. Health-related quality of life and associated

8(1):22–30
26. Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and
KPS are independent prognostic factors in stage I non-small

psychosocial factors in irritable bowel syndrome: a review.

cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52(4):1047–

Qual Life Res 2000;9(2):161–176

1057

13. Camilleri M, Bueno L, de Ponti F, Fioramonti J, Lydiard RB,
Tack J. Pharmacological and pharmacokinetic aspects of

27. Birim O, Maat APWM, Kappetein AP, van Meerbeeck JP,
Damhuis RA, Bogers AJ. Validation of the Charlson comor-

functional gastrointestinal disorders. Gastroenterol 2006;

bidity index in patients with operated primary non-small cell

130(5):1421–1434
14. Longstreth GF. Avoiding unnecessary surgery in irritable
bowel syndrome. Gut 2007;56(5):608–610
15. Hasler WL, Schoenfeld P. Systematic review: abdominal and
pelvic surgery in patients with irritable bowel syndrome.
Aliment Pharmacol Ther 2003;17(8):997–1005
16. Cole JA, Yeaw JM, Cutone JA, Kuo B, Huang Z, Earnest DL et
al. The incidence of abdominal and pelvic surgery among
patients with irritable bowel syndrome. Dig Dis Sci 2005;
50(12):2268–2275

lung cancer. Eur J Cardiothorac Surg 2003;23(1):30–34
28. Rieker JR, Hammer E, Eisele R, Schmid E, Hogel J. The impact
of comorbidity on the overall survival and the cause of death
in patients after colorectal cancer resection. Langenbecks Arch
Surg 2002;387(2):72–76
29. Hopman WM, Towheed T, Anastassiades T, Tenehouse A,
Poliquin S, Berger C et al. Canadian normative data for the SF36 health survey. CMAJ 2000;163(3):265–271
30. Angst F, Aeschlimann A, Stucki G. Smallest detectable and
minimal clinically important differences of rehabilitation

17. Li S, Yu Y, Prakash R. Possible pathogenetic roles of abdominal

intervention with their implications for required sample sizes

surgery in irritable bowel syndrome. Med Hypotheses 2011;

using WOMAC and SF-36 quality of life measurement

76(4):497–499

instruments in patients with osteoarthritis of the lower

18. Brazier JE, Harper R, Jones NMB, O’Cathain A, Thomas KJ,
Usherwood T et al. Validating the SF-36 health survey
questionnaire: new outcome measure for primary care. BMJ
1992;305(6846):160–164
19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form
health survey (SF-36). I. Conceptual framework and item
selection. Med Care 1992;30(6):473–483

extremities. Arthritis Care Res 2001;45(1):384–391
31. Hays RD, Morales LS. The RAND-36 measure of healthrelated quality of life. Ann Med 2001;33(5):350–357
32. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A et
al. Activation of the mucosal immune system in irritable bowel
syndrome. Gastroenterol 2002;122(7):1778–1783
33. Kellow JE, Azpiroz F, Delvaux M, Gebhart GF, Mertz HR,

20. Groll D, Vanner SJ, Depew WT, Dacosta LR, Simon JB, Groll A

Quigley EMM et al. Applied principles of neurogastroenter-

et al. The IBS-36: a new quality of life measure for irritable
bowel syndrome. Am J Gastroenterol 2002;97(4):962–971
21. Charlson ME, Pompei P, Ales K, MacKenzie CR. A new

ology: physiology/motility sensation. Gastroenterol 2006;
130(5):1412–1420

method of classifying prognostic comorbidity in longitudinal

34. Tornblom H, Lindberg G, Nyberg B, Veress B. Full thickness

studies: development and validation. J Chron Dis 1987;40(5):

biopsy of the jejunum reveals inflammation and enteric
neuropathy in irritable bowel syndrome. Gastroenterol 2002;

373–383

123(6):1972–1979

Int Surg 2015;100

69

Downloaded from http://meridian.allenpress.com/international-surgery/article-pdf/100/1/63/2215111/intsurg-d-13-00212_1.pdf by guest on 28 June 2022

Carlsson J et al. Impact of irritable bowel syndrome on

